AK150
/ Akesobio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 15, 2026
Akeso…announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors
(PRNewswire)
- "AK150 is currently the only ILT2/ILT4/CSF1R trispecific antibody under development globally and is also Akeso's first trispecific molecule to enter the clinical stage."
New trial • Solid Tumor
1 to 1
Of
1
Go to page
1